Pharmaceutical Market by API Type (Synthetic API, Biotech API); by Drug Type (Prescription Drugs, OTC Drugs); by Customer Base Type (Generic Drugs, Branded Drugs); by Application Type ( Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Gastrointestinal Disorders, Nephrology, Ophthalmology, Others) by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth Size, Comparative Analysis, Trends and Forecast, 2018 - 2026
Industry Trends
The pharmaceutical industry is engaged in the research, development, manufacture and distribution of drugs for human or veterinary use. Drug therapy is an integral part of every aspect of healthcare. New drugs have an enormous positive influence on global health, economic productivity by saving lives, increasing life spans, reducing suffering, shortening hospital stays and preventing surgeries. The United States attracts the majority of global venture capital investments in start-up companies. It has one of the world’s most supportive domestic environments for the commercialization and development of pharmaceuticals with minimal market barriers. U.S. laws allow direct-to-consumer advertising which creates immense demand for specific patented drugs. In terms of revenue, the pharmaceutical market was valued at US$ 1350.29 Bn in 2017 and is expected to reach US$ 1809.09 Bn by 2022.
Pharmaceutical Market, by Region, 2018-2026 (US$ Billion)
Growing segments of the market include biologics and generics. Increase in the size of middle class households coupled with the improvement in medical infrastructure has resulted in the growth of pharmaceuticals sector. With increasing urbanization and concerns related to day to day living in urban settings, about 50 percent spending on in-patient beds is for lifestyle diseases which has increased the demand for specialized care. Increasing competition from generics is a major factor hampering the growth of global pharmaceutical market. However, the implementation of the Goods and Services Tax (GST) is expected to be a game-changer for the industry leading to tax-neutral inter-state transactions between two dealers. It is expected to result in an efficient supply chain management, which is expected to reduce its cost considerably.
Market by Drug Type
Based on the drug type, the market is segmented into prescription drugs and OTC drugs. Among these, prescription drugs segment is dominating the overall pharmaceutical market. Prescription drug legally requires a medical prescription to be dispensed whereas, over the counter (OTC) drugs can be obtained without a prescription. Increasing patient involvement in the diagnosis and treatment of common ailments is leading to an increase in the use of prescription drug products.
Pharmaceutical Market, by Region
The global market is categorized into North America, Europe, Asia Pacific, the Middle East & Africa and Latin America. North America dominates the market and is anticipated to grow at a considerable rate over the forecast period, where U.S. contributed the highest market share in the overall market. The rising number of ailments has facilitated increased R&D activities by major pharmaceutical companies, which has resulted in tremendous progress of pharmaceutical market in this region.
Competitive Landscape
The report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.
Market participants of the pharmaceutical market are Abbott, AbbVie Inc., Albemarle Corporation, AstraZeneca, Aurobindo Pharma, Baxter, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Sanofi and Teva Pharmaceutical Industries Ltd amongst others.
Pharmaceutical Market Background
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Methodology
1.4. Assumptions
2. Pharmaceutical Market Snapshot
3. Executive Summary: Pharmaceutical Market
4. Qualitative Analysis: Pharmaceutical Market
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Development
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
5. Global Pharmaceutical Market Analysis and Forecasts, 2018 -
2026
5.1. Overview
5.1.1. Global Market Revenue (US$ Mn) and Forecasts
5.2. Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
5.2.1. Synthetic Active Pharmaceutical Ingredients
5.2.1.1. Definition
5.2.1.2. Market Penetration
5.2.1.3. Market Revenue Expected to Increase by 2026
5.2.1.4. Compound Annual Growth Rate (CAGR)
5.2.2. Biotech Active Pharmaceutical Ingredients (Definition, Market
Penetration, Market Revenue Expected to Increase by 2026, Compound Annual
Growth Rate (CAGR) and information on sub segments)
5.2.2.1.
Monoclonal Antibodies
5.2.2.2.
Vaccines
5.2.2.3.
Hormones and Growth
Factors
5.2.2.4.
Cytokines
5.2.2.5.
Fusion Proteins
5.2.2.6.
Therapeutic Enzymes
5.2.2.7.
Blood Factors
5.3. Key Segment for Channeling Investments
5.3.1. By Active Pharmaceutical Ingredients Type
6. Global Pharmaceutical Market Analysis and Forecasts, 2018 -
2026
6.1. Overview
6.2. Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Drug Type
6.2.1. Prescription Drugs
6.2.1.1. Definition
6.2.1.2. Market Penetration
6.2.1.3. Market Revenue Expected to Increase by 2026
6.2.1.4. Compound Annual Growth Rate (CAGR)
6.2.2. Over-The-Counter Drugs
6.2.2.1. Definition
6.2.2.2. Market Penetration
6.2.2.3. Market Revenue Expected to Increase by 2026
6.2.2.4. Compound Annual Growth Rate (CAGR)
6.3. Key Segment for Channeling Investments
6.3.1. By Drug Type
7. Global Pharmaceutical Market Analysis and Forecasts, 2018 -
2026
7.1. Overview
7.2. Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Customer Base
7.2.1. Generic
7.2.1.1. Definition
7.2.1.2. Market Penetration
7.2.1.3. Market Revenue Expected to Increase by 2026
7.2.1.4. Compound Annual Growth Rate (CAGR)
7.2.2. Branded
7.2.2.1. Definition
7.2.2.2. Market Penetration
7.2.2.3. Market Revenue Expected to Increase by 2026
7.2.2.4. Compound Annual Growth Rate (CAGR)
7.3. Key Segment for Channeling Investments
7.3.1. By Customer Base
8. Global Pharmaceutical Market Analysis and Forecasts, 2018 -
2026
8.1. Overview
8.2. Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Application
8.2.1. Oncology
8.2.1.1. Definition
8.2.1.2. Market Penetration
8.2.1.3. Market Revenue Expected to Increase by 2026
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.2. Cardiovascular Disease
8.2.2.1. Definition
8.2.2.2. Market Penetration
8.2.2.3. Market Revenue Expected to Increase by 2026
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.3. Diabetes
8.2.3.1. Definition
8.2.3.2. Market Penetration
8.2.3.3. Market Revenue Expected to Increase by 2026
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.4. Central Nervous System and Neurological Disorders
8.2.4.1. Definition
8.2.4.2. Market Penetration
8.2.4.3. Market Revenue Expected to Increase by 2026
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.5. Endocrinology
8.2.5.1. Definition
8.2.5.2. Market Penetration
8.2.5.3. Market Revenue Expected to Increase by 2026
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.6. Gastrointestinal Disorders
8.2.6.1. Definition
8.2.6.2. Market Penetration
8.2.6.3. Market Revenue Expected to Increase by 2026
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.7. Nephrology
8.2.7.1. Definition
8.2.7.2. Market Penetration
8.2.7.3. Market Revenue Expected to Increase by 2026
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.8. Ophthalmology
8.2.8.1. Definition
8.2.8.2. Market Penetration
8.2.8.3. Market Revenue Expected to Increase by 2026
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.3. Key Segment for Channeling Investments
8.3.1. By Application
9. North America Pharmaceutical Market Analysis and Forecasts, 2018
- 2026
9.1. Overview
9.1.1. North America Market Revenue (US$ Mn)
9.2. North America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
9.2.1. Synthetic Active Pharmaceutical Ingredients
9.2.2.
Biotech Active
Pharmaceutical Ingredients
9.2.2.1.
Monoclonal Antibodies
9.2.2.2.
Vaccines
9.2.2.3.
Hormones and Growth
Factors
9.2.2.4.
Cytokines
9.2.2.5.
Fusion Proteins
9.2.2.6.
Therapeutic Enzymes
9.2.2.7.
Blood Factors
9.3. North America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
9.3.1. Prescription Drugs
9.3.2. Over-The-Counter Drugs
9.4. North America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Customer Base
9.4.1. Generic
9.4.2. Branded
9.5. North America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Application
9.5.1. Oncology
9.5.2. Cardiovascular Disease
9.5.3. Diabetes
9.5.4. Central Nervous System and Neurological Disorders
9.5.5. Endocrinology
9.5.6. Gastrointestinal Disorders
9.5.7. Nephrology
9.5.8. Ophthalmology
9.6. North America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Country
9.6.1. U.S.
9.6.1.1. U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
9.6.1.1.1. Synthetic Active Pharmaceutical Ingredients
9.6.1.1.2.
Biotech Active
Pharmaceutical Ingredients
9.6.1.1.2.1.
Monoclonal Antibodies
9.6.1.1.2.2.
Vaccines
9.6.1.1.2.3.
Hormones and Growth
Factors
9.6.1.1.2.4.
Cytokines
9.6.1.1.2.5.
Fusion Proteins
9.6.1.1.2.6.
Therapeutic Enzymes
9.6.1.1.2.7.
Blood Factors
9.6.1.2. U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Drug Type
9.6.1.2.1. Prescription Drugs
9.6.1.2.2. Over-The-Counter Drugs
9.6.1.3. U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Customer Base
9.6.1.3.1. Generic
9.6.1.3.2. Branded
9.6.1.4. U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Application
9.6.1.4.1. Oncology
9.6.1.4.2. Cardiovascular Disease
9.6.1.4.3. Diabetes
9.6.1.4.4. Central Nervous System and Neurological Disorders
9.6.1.4.5. Endocrinology
9.6.1.4.6. Gastrointestinal Disorders
9.6.1.4.7. Nephrology
9.6.1.4.8. Ophthalmology
9.6.2. Rest of North America
9.6.2.1. Rest of North America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Active Pharmaceutical Ingredients Type
9.6.2.1.1. Synthetic Active Pharmaceutical Ingredients
9.6.2.1.2.
Biotech Active
Pharmaceutical Ingredients
9.6.2.1.2.1.
Monoclonal Antibodies
9.6.2.1.2.2.
Vaccines
9.6.2.1.2.3.
Hormones and Growth
Factors
9.6.2.1.2.4.
Cytokines
9.6.2.1.2.5.
Fusion Proteins
9.6.2.1.2.6.
Therapeutic Enzymes
9.6.2.1.2.7.
Blood Factors
9.6.2.2. Rest of North America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Drug Type
9.6.2.2.1. Prescription Drugs
9.6.2.2.2. Over-The-Counter Drugs
9.6.2.3. Rest of North America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Customer Base
9.6.2.3.1. Generic
9.6.2.3.2. Branded
9.6.2.4. Rest of North America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Application
9.6.2.4.1. Oncology
9.6.2.4.2. Cardiovascular Disease
9.6.2.4.3. Diabetes
9.6.2.4.4. Central Nervous System and Neurological Disorders
9.6.2.4.5. Endocrinology
9.6.2.4.6. Gastrointestinal Disorders
9.6.2.4.7. Nephrology
9.6.2.4.8. Ophthalmology
9.7. Key Segment for Channeling Investments
9.7.1. By Country
9.7.2. By Active Pharmaceutical Ingredients Type
9.7.3. By Drug Type
9.7.4. By Customer Base
9.7.5. By Application
10. Europe Pharmaceutical Market Analysis and Forecasts, 2018 -
2026
10.1. Overview
10.1.1. Europe Market Revenue (US$ Mn)
10.2. Europe Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
10.2.1. Synthetic Active Pharmaceutical Ingredients
10.2.2. Biotech Active Pharmaceutical Ingredients
10.2.2.1.
Monoclonal Antibodies
10.2.2.2.
Vaccines
10.2.2.3.
Hormones and Growth
Factors
10.2.2.4.
Cytokines
10.2.2.5.
Fusion Proteins
10.2.2.6.
Therapeutic Enzymes
10.2.2.7.
Blood Factors
10.3. Europe Market Revenue (US$ Mn) and Forecasts, By Drug Type
10.3.1. Prescription Drugs
10.3.2. Over-The-Counter Drugs
10.4. Europe Market Revenue (US$ Mn) and Forecasts, By Customer Base
10.4.1. Generic
10.4.2. Branded
10.5. Europe Market Revenue (US$ Mn) and Forecasts, By Application
10.5.1. Oncology
10.5.2. Cardiovascular Disease
10.5.3. Diabetes
10.5.4. Central Nervous System and Neurological Disorders
10.5.5. Endocrinology
10.5.6. Gastrointestinal Disorders
10.5.7. Nephrology
10.5.8. Ophthalmology
10.6. Europe Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Country
10.6.1. France
10.6.1.1. France Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
10.6.1.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.1.1.2.
Biotech Active
Pharmaceutical Ingredients
10.6.1.1.2.1.
Monoclonal Antibodies
10.6.1.1.2.2.
Vaccines
10.6.1.1.2.3.
Hormones and Growth
Factors
10.6.1.1.2.4.
Cytokines
10.6.1.1.2.5.
Fusion Proteins
10.6.1.1.2.6.
Therapeutic Enzymes
10.6.1.1.2.7.
Blood Factors
10.6.1.2. France Market Revenue (US$ Mn) and Forecasts, By Drug Type
10.6.1.2.1. Prescription Drugs
10.6.1.2.2. Over-The-Counter Drugs
10.6.1.3. France Market Revenue (US$ Mn) and Forecasts, By Customer Base
10.6.1.3.1. Generic
10.6.1.3.2. Branded
10.6.1.4. France Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Application
10.6.1.4.1. Oncology
10.6.1.4.2. Cardiovascular Disease
10.6.1.4.3. Diabetes
10.6.1.4.4. Central Nervous System and Neurological Disorders
10.6.1.4.5. Endocrinology
10.6.1.4.6. Gastrointestinal Disorders
10.6.1.4.7. Nephrology
10.6.1.4.8. Ophthalmology
10.6.2. The U.K.
10.6.2.1. The U.K. Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
10.6.2.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.2.1.2.
Biotech Active
Pharmaceutical Ingredients
10.6.2.1.2.1.
Monoclonal Antibodies
10.6.2.1.2.2.
Vaccines
10.6.2.1.2.3.
Hormones and Growth
Factors
10.6.2.1.2.4.
Cytokines
10.6.2.1.2.5.
Fusion Proteins
10.6.2.1.2.6.
Therapeutic Enzymes
10.6.2.1.2.7.
Blood Factors
10.6.2.2. The U.K. Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Drug Type
10.6.2.2.1. Prescription Drugs
10.6.2.2.2. Over-The-Counter Drugs
10.6.2.3. The U.K. Market Revenue (US$ Mn) and Forecasts, By Customer
Base
10.6.2.3.1. Generic
10.6.2.3.2. Branded
10.6.2.4. The U.K. Market Revenue (US$ Mn) and Forecasts, By Application
10.6.2.4.1. Oncology
10.6.2.4.2. Cardiovascular Disease
10.6.2.4.3. Diabetes
10.6.2.4.4. Central Nervous System and Neurological Disorders
10.6.2.4.5. Endocrinology
10.6.2.4.6. Gastrointestinal Disorders
10.6.2.4.7. Nephrology
10.6.2.4.8. Ophthalmology
10.6.3. Spain
10.6.3.1. Spain Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
10.6.3.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.3.1.2.
Biotech Active
Pharmaceutical Ingredients
10.6.3.1.2.1.
Monoclonal Antibodies
10.6.3.1.2.2.
Vaccines
10.6.3.1.2.3.
Hormones and Growth
Factors
10.6.3.1.2.4.
Cytokines
10.6.3.1.2.5.
Fusion Proteins
10.6.3.1.2.6.
Therapeutic Enzymes
10.6.3.1.2.7.
Blood Factors
10.6.3.2. Spain Market Revenue (US$ Mn) and Forecasts, By Drug Type
10.6.3.2.1. Prescription Drugs
10.6.3.2.2. Over-The-Counter Drugs
10.6.3.3. Spain Market Revenue (US$ Mn) and Forecasts, By Customer Base
10.6.3.3.1. Generic
10.6.3.3.2. Branded
10.6.3.4. Spain Market Revenue (US$ Mn) and Forecasts, By Application
10.6.3.4.1. Oncology
10.6.3.4.2. Cardiovascular Disease
10.6.3.4.3. Diabetes
10.6.3.4.4. Central Nervous System and Neurological Disorders
10.6.3.4.5. Endocrinology
10.6.3.4.6. Gastrointestinal Disorders
10.6.3.4.7. Nephrology
10.6.3.4.8. Ophthalmology
10.6.4. Germany
10.6.4.1. Germany Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
10.6.4.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.4.1.2.
Biotech Active Pharmaceutical
Ingredients
10.6.4.1.2.1.
Monoclonal Antibodies
10.6.4.1.2.2.
Vaccines
10.6.4.1.2.3.
Hormones and Growth
Factors
10.6.4.1.2.4.
Cytokines
10.6.4.1.2.5.
Fusion Proteins
10.6.4.1.2.6.
Therapeutic Enzymes
10.6.4.1.2.7.
Blood Factors
10.6.4.2. Germany Market Revenue (US$ Mn) and Forecasts, By Drug Type
10.6.4.2.1. Prescription Drugs
10.6.4.2.2. Over-The-Counter Drugs
10.6.4.3. Germany Market Revenue (US$ Mn) and Forecasts, By Customer
Base
10.6.4.3.1. Generic
10.6.4.3.2. Branded
10.6.4.4. Germany Market Revenue (US$ Mn) and Forecasts, By Application
10.6.4.4.1. Oncology
10.6.4.4.2. Cardiovascular Disease
10.6.4.4.3. Diabetes
10.6.4.4.4. Central Nervous System and Neurological Disorders
10.6.4.4.5. Endocrinology
10.6.4.4.6. Gastrointestinal Disorders
10.6.4.4.7. Nephrology
10.6.4.4.8. Ophthalmology
10.6.5. Italy
10.6.5.1. Italy Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
10.6.5.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.5.1.2.
Biotech Active
Pharmaceutical Ingredients
10.6.5.1.2.1.
Monoclonal Antibodies
10.6.5.1.2.2.
Vaccines
10.6.5.1.2.3.
Hormones and Growth
Factors
10.6.5.1.2.4.
Cytokines
10.6.5.1.2.5.
Fusion Proteins
10.6.5.1.2.6.
Therapeutic Enzymes
10.6.5.1.2.7.
Blood Factors
10.6.5.2. Italy Market Revenue (US$ Mn) and Forecasts, By Drug Type
10.6.5.2.1. Prescription Drugs
10.6.5.2.2. Over-The-Counter Drugs
10.6.5.3. Italy Market Revenue (US$ Mn) and Forecasts, By Customer Base
10.6.5.3.1. Generic
10.6.5.3.2. Branded
10.6.5.4. Italy Market Revenue (US$ Mn) and Forecasts, By Application
10.6.5.4.1. Oncology
10.6.5.4.2. Cardiovascular Disease
10.6.5.4.3. Diabetes
10.6.5.4.4. Central Nervous System and Neurological Disorders
10.6.5.4.5. Endocrinology
10.6.5.4.6. Gastrointestinal Disorders
10.6.5.4.7. Nephrology
10.6.5.4.8. Ophthalmology
10.6.6. Rest of Europe
10.6.6.1. Rest of Europe Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
10.6.6.1.1. Synthetic Active Pharmaceutical Ingredients
10.6.6.1.2.
Biotech Active
Pharmaceutical Ingredients
10.6.6.1.2.1.
Monoclonal Antibodies
10.6.6.1.2.2.
Vaccines
10.6.6.1.2.3.
Hormones and Growth
Factors
10.6.6.1.2.4.
Cytokines
10.6.6.1.2.5.
Fusion Proteins
10.6.6.1.2.6.
Therapeutic Enzymes
10.6.6.1.2.7.
Blood Factors
10.6.6.2. Rest of Europe Market Revenue (US$ Mn) and Forecasts, By Drug
Type
10.6.6.2.1. Prescription Drugs
10.6.6.2.2. Over-The-Counter Drugs
10.6.6.3. Rest of Europe Market Revenue (US$ Mn) and Forecasts, By
Customer Base
10.6.6.3.1. Generic
10.6.6.3.2. Branded
10.6.6.4. Rest of Europe Market Revenue (US$ Mn) and Forecasts, By
Application
10.6.6.4.1. Oncology
10.6.6.4.2. Cardiovascular Disease
10.6.6.4.3. Diabetes
10.6.6.4.4. Central Nervous System and Neurological Disorders
10.6.6.4.5. Endocrinology
10.6.6.4.6. Gastrointestinal Disorders
10.6.6.4.7. Nephrology
10.6.6.4.8. Ophthalmology
10.7. Key Segment for Channeling Investments
10.7.1. By Country
10.7.2. By Active Pharmaceutical Ingredients Type
10.7.3. By Drug Type
10.7.4. By Customer Base
10.7.5. By Application
11. Asia Pacific
Pharmaceutical Market Analysis and Forecasts, 2018 - 2026
11.1. Overview
11.1.1. Asia Pacific Pharmaceutical Market Revenue (US$ Mn)
11.2. Asia Pacific Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
11.2.1. Synthetic Active Pharmaceutical Ingredients
11.2.2. Biotech Active Pharmaceutical Ingredients
11.2.2.1.
Monoclonal Antibodies
11.2.2.2.
Vaccines
11.2.2.3.
Hormones and Growth
Factors
11.2.2.4.
Cytokines
11.2.2.5.
Fusion Proteins
11.2.2.6.
Therapeutic Enzymes
11.2.2.7.
Blood Factors
11.3. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Drug
Type
11.3.1. Prescription Drugs
11.3.2. Over-The-Counter Drugs
11.4. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By
Customer Base
11.4.1. Generic
11.4.2. Branded
11.5. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.1. Oncology
11.5.2. Cardiovascular Disease
11.5.3. Diabetes
11.5.4. Central Nervous System and Neurological Disorders
11.5.5. Endocrinology
11.5.6. Gastrointestinal Disorders
11.5.7. Nephrology
11.5.8. Ophthalmology
11.6. Asia Pacific Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Country
11.6.1. China
11.6.1.1. China Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
11.6.1.1.1. Synthetic Active Pharmaceutical Ingredients
11.6.1.1.2.
Biotech Active
Pharmaceutical Ingredients
11.6.1.1.2.1.
Monoclonal Antibodies
11.6.1.1.2.2.
Vaccines
11.6.1.1.2.3.
Hormones and Growth
Factors
11.6.1.1.2.4.
Cytokines
11.6.1.1.2.5.
Fusion Proteins
11.6.1.1.2.6.
Therapeutic Enzymes
11.6.1.1.2.7.
Blood Factors
11.6.1.2. China Market Revenue (US$ Mn) and Forecasts, By Drug Type
11.6.1.2.1. Prescription Drugs
11.6.1.2.2. Over-The-Counter Drugs
11.6.1.3. China Market Revenue (US$ Mn) and Forecasts, By Customer Base
11.6.1.3.1. Generic
11.6.1.3.2. Branded
11.6.1.4. China Market Revenue (US$ Mn) and Forecasts, By Application
11.6.1.4.1. Oncology
11.6.1.4.2. Cardiovascular Disease
11.6.1.4.3. Diabetes
11.6.1.4.4. Central Nervous System and Neurological Disorders
11.6.1.4.5. Endocrinology
11.6.1.4.6. Gastrointestinal Disorders
11.6.1.4.7. Nephrology
11.6.1.4.8. Ophthalmology
11.6.2. Japan
11.6.2.1. Japan Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
11.6.2.1.1. Synthetic Active Pharmaceutical Ingredients
11.6.2.1.2.
Biotech Active
Pharmaceutical Ingredients
11.6.2.1.2.1.
Monoclonal Antibodies
11.6.2.1.2.2.
Vaccines
11.6.2.1.2.3.
Hormones and Growth
Factors
11.6.2.1.2.4.
Cytokines
11.6.2.1.2.5.
Fusion Proteins
11.6.2.1.2.6.
Therapeutic Enzymes
11.6.2.1.2.7.
Blood Factors
11.6.2.2. Japan Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Drug Type
11.6.2.2.1. Prescription Drugs
11.6.2.2.2. Over-The-Counter Drugs
11.6.2.3. Japan Market Revenue (US$ Mn) and Forecasts, By Customer Base
11.6.2.3.1. Generic
11.6.2.3.2. Branded
11.6.2.4. Japan Market Revenue (US$ Mn) and Forecasts, By Application
11.6.2.4.1. Oncology
11.6.2.4.2. Cardiovascular Disease
11.6.2.4.3. Diabetes
11.6.2.4.4. Central Nervous System and Neurological Disorders
11.6.2.4.5. Endocrinology
11.6.2.4.6. Gastrointestinal Disorders
11.6.2.4.7. Nephrology
11.6.2.4.8. Ophthalmology
11.6.3. India
11.6.3.1. India Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Active Pharmaceutical Ingredients Type
11.6.3.1.1. Synthetic Active Pharmaceutical Ingredients
11.6.3.1.2.
Biotech Active
Pharmaceutical Ingredients
11.6.3.1.2.1.
Monoclonal Antibodies
11.6.3.1.2.2.
Vaccines
11.6.3.1.2.3.
Hormones and Growth
Factors
11.6.3.1.2.4.
Cytokines
11.6.3.1.2.5.
Fusion Proteins
11.6.3.1.2.6.
Therapeutic Enzymes
11.6.3.1.2.7.
Blood Factors
11.6.3.2. India Market Revenue (US$ Mn) and Forecasts, By Drug Type
11.6.3.2.1. Prescription Drugs
11.6.3.2.2. Over-The-Counter Drugs
11.6.3.3. India Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By
Customer Base
11.6.3.3.1. Generic
11.6.3.3.2. Branded
11.6.3.4. India Market Revenue (US$ Mn) and Forecasts, By Application
11.6.3.4.1. Oncology
11.6.3.4.2. Cardiovascular Disease
11.6.3.4.3. Diabetes
11.6.3.4.4. Central Nervous System and Neurological Disorders
11.6.3.4.5. Endocrinology
11.6.3.4.6. Gastrointestinal Disorders
11.6.3.4.7. Nephrology
11.6.3.4.8. Ophthalmology
11.6.4. Southeast Asia
11.6.4.1. Southeast Asia Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
11.6.4.1.1. Synthetic Active Pharmaceutical Ingredients
11.6.4.1.2.
Biotech Active
Pharmaceutical Ingredients
11.6.4.1.2.1.
Monoclonal Antibodies
11.6.4.1.2.2.
Vaccines
11.6.4.1.2.3.
Hormones and Growth
Factors
11.6.4.1.2.4.
Cytokines
11.6.4.1.2.5.
Fusion Proteins
11.6.4.1.2.6.
Therapeutic Enzymes
11.6.4.1.2.7.
Blood Factors
11.6.4.2. Southeast Asia Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
11.6.4.2.1. Prescription Drugs
11.6.4.2.2. Over-The-Counter Drugs
11.6.4.3. Southeast Asia Market Revenue (US$ Mn) and Forecasts, By
Customer Base
11.6.4.3.1. Generic
11.6.4.3.2. Branded
11.6.4.4. Southeast Asia Market Revenue (US$ Mn) and Forecasts, By
Application
11.6.4.4.1. Oncology
11.6.4.4.2. Cardiovascular Disease
11.6.4.4.3. Diabetes
11.6.4.4.4. Central Nervous System and Neurological Disorders
11.6.4.4.5. Endocrinology
11.6.4.4.6. Gastrointestinal Disorders
11.6.4.4.7. Nephrology
11.6.4.4.8. Ophthalmology
11.6.5. Rest of Asia Pacific
11.6.5.1. Rest of Asia Pacific Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Active Pharmaceutical Ingredients Type
11.6.5.1.1. Synthetic Active Pharmaceutical Ingredients
11.6.5.1.2.
Biotech Active
Pharmaceutical Ingredients
11.6.5.1.2.1.
Monoclonal Antibodies
11.6.5.1.2.2.
Vaccines
11.6.5.1.2.3.
Hormones and Growth
Factors
11.6.5.1.2.4.
Cytokines
11.6.5.1.2.5.
Fusion Proteins
11.6.5.1.2.6.
Therapeutic Enzymes
11.6.5.1.2.7.
Blood Factors
11.6.5.2. Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By
Drug Type
11.6.5.2.1. Prescription Drugs
11.6.5.2.2. Over-The-Counter Drugs
11.6.5.3. Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By
Customer Base
11.6.5.3.1. Generic
11.6.5.3.2. Branded
11.6.5.4. Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By
Application
11.6.5.4.1. Oncology
11.6.5.4.2. Cardiovascular Disease
11.6.5.4.3. Diabetes
11.6.5.4.4. Central Nervous System and Neurological Disorders
11.6.5.4.5. Endocrinology
11.6.5.4.6. Gastrointestinal Disorders
11.6.5.4.7. Nephrology
11.6.5.4.8. Ophthalmology
11.7. Key Segment for Channeling Investments
11.7.1. By Country
11.7.2. By Active Pharmaceutical Ingredients Type
11.7.3. By Drug Type
11.7.4. By Customer Base
11.7.5. By Application
12. Middle East and Africa Pharmaceutical Market Analysis and
Forecasts, 2018 - 2026
12.1. Overview
12.1.1. Middle East and Africa Market Revenue (US$ Mn)
12.2. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Active Pharmaceutical Ingredients Type
12.2.1. Synthetic Active Pharmaceutical Ingredients
12.2.2. Biotech Active Pharmaceutical Ingredients
12.2.2.1.
Monoclonal Antibodies
12.2.2.2.
Vaccines
12.2.2.3.
Hormones and Growth
Factors
12.2.2.4.
Cytokines
12.2.2.5.
Fusion Proteins
12.2.2.6.
Therapeutic Enzymes
12.2.2.7.
Blood Factors
12.3. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Drug Type
12.3.1. Prescription Drugs
12.3.2. Over-The-Counter Drugs
12.4. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Customer Base
12.4.1. Generic
12.4.2. Branded
12.5. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.1. Oncology
12.5.2. Cardiovascular Disease
12.5.3. Diabetes
12.5.4. Central Nervous System and Neurological Disorders
12.5.5. Endocrinology
12.5.6. Gastrointestinal Disorders
12.5.7. Nephrology
12.5.8. Ophthalmology
12.6. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Country
12.6.1. GCC Countries
12.6.1.1. GCC Countries Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
12.6.1.1.1. Synthetic Active Pharmaceutical Ingredients
12.6.1.1.2.
Biotech Active
Pharmaceutical Ingredients
12.6.1.1.2.1.
Monoclonal Antibodies
12.6.1.1.2.2.
Vaccines
12.6.1.1.2.3.
Hormones and Growth
Factors
12.6.1.1.2.4.
Cytokines
12.6.1.1.2.5.
Fusion Proteins
12.6.1.1.2.6.
Therapeutic Enzymes
12.6.1.1.2.7.
Blood Factors
12.6.1.2. GCC Countries Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.6.1.2.1. Prescription Drugs
12.6.1.2.2. Over-The-Counter Drugs
12.6.1.3. GCC Countries Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Customer Base
12.6.1.3.1. Generic
12.6.1.3.2. Branded
12.6.1.4. GCC Countries Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.4.1. Oncology
12.6.1.4.2. Cardiovascular Disease
12.6.1.4.3. Diabetes
12.6.1.4.4. Central Nervous System and Neurological Disorders
12.6.1.4.5. Endocrinology
12.6.1.4.6. Gastrointestinal Disorders
12.6.1.4.7. Nephrology
12.6.1.4.8. Ophthalmology
12.6.2. Southern Africa
12.6.2.1. Southern Africa Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
12.6.2.1.1. Synthetic Active Pharmaceutical Ingredients
12.6.2.1.2.
Biotech Active
Pharmaceutical Ingredients
12.6.2.1.2.1.
Monoclonal Antibodies
12.6.2.1.2.2.
Vaccines
12.6.2.1.2.3.
Hormones and Growth
Factors
12.6.2.1.2.4.
Cytokines
12.6.2.1.2.5.
Fusion Proteins
12.6.2.1.2.6.
Therapeutic Enzymes
12.6.2.1.2.7.
Blood Factors
12.6.2.2. Southern Africa Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.6.2.2.1. Prescription Drugs
12.6.2.2.2. Over-The-Counter Drugs
12.6.2.3. Southern Africa Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Customer Base
12.6.2.3.1. Generic
12.6.2.3.2. Branded
12.6.2.4. Southern Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.2.4.1. Oncology
12.6.2.4.2. Cardiovascular Disease
12.6.2.4.3. Diabetes
12.6.2.4.4. Central Nervous System and Neurological Disorders
12.6.2.4.5. Endocrinology
12.6.2.4.6. Gastrointestinal Disorders
12.6.2.4.7. Nephrology
12.6.2.4.8. Ophthalmology
12.6.3. Rest of MEA
12.6.3.1. Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
12.6.3.1.1. Synthetic Active Pharmaceutical Ingredients
12.6.3.1.2.
Biotech Active
Pharmaceutical Ingredients
12.6.3.1.2.1.
Monoclonal Antibodies
12.6.3.1.2.2.
Vaccines
12.6.3.1.2.3.
Hormones and Growth
Factors
12.6.3.1.2.4.
Cytokines
12.6.3.1.2.5.
Fusion Proteins
12.6.3.1.2.6.
Therapeutic Enzymes
12.6.3.1.2.7.
Blood Factors
12.6.3.2. Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.6.3.2.1. Prescription Drugs
12.6.3.2.2. Over-The-Counter Drugs
12.6.3.3. Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Customer Base
12.6.3.3.1. Generic
12.6.3.3.2. Branded
12.6.3.4. Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.4.1. Oncology
12.6.3.4.2. Cardiovascular Disease
12.6.3.4.3. Diabetes
12.6.3.4.4. Central Nervous System and Neurological Disorders
12.6.3.4.5. Endocrinology
12.6.3.4.6. Gastrointestinal Disorders
12.6.3.4.7. Nephrology
12.6.3.4.8. Ophthalmology
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Active Pharmaceutical Ingredients Type
12.7.3. By Drug Type
12.7.4. By Customer Base
12.7.5. By Application
13. Latin America Pharmaceutical Market Analysis and Forecasts, 2018
- 2026
13.1. Overview
13.1.1. Latin America Pharmaceutical Market Revenue (US$ Mn)
13.2. Latin America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Active Pharmaceutical Ingredients Type
13.2.1. Synthetic Active Pharmaceutical Ingredients
13.2.2. Biotech Active Pharmaceutical Ingredients
13.2.2.1.1.1.
Monoclonal Antibodies
13.2.2.1.1.2.
Vaccines
13.2.2.1.1.3.
Hormones and Growth
Factors
13.2.2.1.1.4.
Cytokines
13.2.2.1.1.5.
Fusion Proteins
13.2.2.1.1.6.
Therapeutic Enzymes
13.2.2.1.1.7.
Blood Factors
13.3. Latin America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.3.1. Prescription Drugs
13.3.2. Over-The-Counter Drugs
13.4. Latin America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Customer Base
13.4.1. Generic
13.4.2. Branded
13.5. Latin America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.1. Oncology
13.5.2. Cardiovascular Disease
13.5.3. Diabetes
13.5.4. Central Nervous System and Neurological Disorders
13.5.5. Endocrinology
13.5.6. Gastrointestinal Disorders
13.5.7. Nephrology
13.5.8. Ophthalmology
13.6. Latin America Pharmaceutical Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.1. Brazil
13.6.1.1. Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Active Pharmaceutical Ingredients Type
13.6.1.1.1. Synthetic Active Pharmaceutical Ingredients
13.6.1.1.2.
Biotech Active
Pharmaceutical Ingredients
13.6.1.1.2.1.
Monoclonal Antibodies
13.6.1.1.2.2.
Vaccines
13.6.1.1.2.3.
Hormones and Growth
Factors
13.6.1.1.2.4.
Cytokines
13.6.1.1.2.5.
Fusion Proteins
13.6.1.1.2.6.
Therapeutic Enzymes
13.6.1.1.2.7.
Blood Factors
13.6.1.2. Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Drug Type
13.6.1.2.1. Prescription Drugs
13.6.1.2.2. Over-The-Counter Drugs
13.6.1.3. Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Customer Base
13.6.1.3.1. Generic
13.6.1.3.2. Branded
13.6.1.4. Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts,
By Application
13.6.1.4.1. Oncology
13.6.1.4.2. Cardiovascular Disease
13.6.1.4.3. Diabetes
13.6.1.4.4. Central Nervous System and Neurological Disorders
13.6.1.4.5. Endocrinology
13.6.1.4.6. Gastrointestinal Disorders
13.6.1.4.7. Nephrology
13.6.1.4.8. Ophthalmology
13.6.2. Rest of Latin America
13.6.2.1. Rest of Latin America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Active Pharmaceutical Ingredients Type
13.6.2.1.1. Synthetic Active Pharmaceutical Ingredients
13.6.2.1.2.
Biotech Active Pharmaceutical
Ingredients
13.6.2.1.2.1.
Monoclonal Antibodies
13.6.2.1.2.2.
Vaccines
13.6.2.1.2.3.
Hormones and Growth
Factors
13.6.2.1.2.4.
Cytokines
13.6.2.1.2.5.
Fusion Proteins
13.6.2.1.2.6.
Therapeutic Enzymes
13.6.2.1.2.7.
Blood Factors
13.6.2.2. Rest of Latin America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Drug Type
13.6.2.2.1. Prescription Drugs
13.6.2.2.2. Over-The-Counter Drugs
13.6.2.3. Rest of Latin America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Customer Base
13.6.2.3.1. Generic
13.6.2.3.2. Branded
13.6.2.4. Rest of Latin America Pharmaceutical Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.2.4.1. Oncology
13.6.2.4.2. Cardiovascular Disease
13.6.2.4.3. Diabetes
13.6.2.4.4. Central Nervous System and Neurological Disorders
13.6.2.4.5. Endocrinology
13.6.2.4.6. Gastrointestinal Disorders
13.6.2.4.7. Nephrology
13.6.2.4.8. Ophthalmology
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Active Pharmaceutical Ingredients Type
13.7.3. By Drug Type
13.7.4. By Customer Base
13.7.5. By Application
14. Competitive Benchmarking
14.1. Player Positioning Analysis
14.2. Global Presence and Growth Strategies
14.3. Market Share Analysis
15. Player Profiles
15.1. Abbott
15.1.1. Company Details
15.1.2. Company Overview
15.1.3. Product Offerings
15.1.4. Key Developments
15.1.5. Financial Analysis
15.1.6. SWOT Analysis
15.1.7. Business Strategies
15.2. AbbVie Inc.
15.2.1. Company Details
15.2.2. Company Overview
15.2.3. Product Offerings
15.2.4. Key Developments
15.2.5. Financial Analysis
15.2.6. SWOT Analysis
15.2.7. Business Strategies
15.3. Albemarle Corporation
15.3.1. Company Details
15.3.2. Company Overview
15.3.3. Product Offerings
15.3.4. Key Developments
15.3.5. Financial Analysis
15.3.6. SWOT Analysis
15.3.7. Business Strategies
15.4. AstraZeneca
15.4.1. Company Details
15.4.2. Company Overview
15.4.3. Product Offerings
15.4.4. Key Developments
15.4.5. Financial Analysis
15.4.6. SWOT Analysis
15.4.7. Business Strategies
15.5. Aurobindo Pharma
15.5.1. Company Details
15.5.2. Company Overview
15.5.3. Product Offerings
15.5.4. Key Developments
15.5.5. Financial Analysis
15.5.6. SWOT Analysis
15.5.7. Business Strategies
15.6. Baxter
15.6.1. Company Details
15.6.2. Company Overview
15.6.3. Product Offerings
15.6.4. Key Developments
15.6.5. Financial Analysis
15.6.6. SWOT Analysis
15.6.7. Business Strategies
15.7. Bayer AG
15.7.1. Company Details
15.7.2. Company Overview
15.7.3. Product Offerings
15.7.4. Key Developments
15.7.5. Financial Analysis
15.7.6. SWOT Analysis
15.7.7. Business Strategies
15.8. Boehringer Ingelheim International GmbH
15.8.1. Company Details
15.8.2. Company Overview
15.8.3. Product Offerings
15.8.4. Key Developments
15.8.5. Financial Analysis
15.8.6. SWOT Analysis
15.8.7. Business Strategies
15.9. Bristol-Myers Squibb Company
15.9.1. Company Details
15.9.2. Company Overview
15.9.3. Product Offerings
15.9.4. Key Developments
15.9.5. Financial Analysis
15.9.6. SWOT Analysis
15.9.7. Business Strategies
15.10. Dr. Reddy’s Laboratories Ltd.
15.10.1. Company Details
15.10.2. Company Overview
15.10.3. Product Offerings
15.10.4. Key Developments
15.10.5. Financial Analysis
15.10.6. SWOT Analysis
15.10.7. Business Strategies
15.11. Eli Lilly and Company
15.11.1.
Company Details
15.11.2.
Company Overview
15.11.3.
Product Offerings
15.11.4.
Key Developments
15.11.5.
Financial Analysis
15.11.6.
SWOT Analysis
15.11.7.
Business Strategies
15.12. F. Hoffmann-La Roche Ltd
15.12.1.
Company Details
15.12.2.
Company Overview
15.12.3.
Product Offerings
15.12.4.
Key Developments
15.12.5.
Financial Analysis
15.12.6.
SWOT Analysis
15.12.7.
Business Strategies
15.13. Glaxosmithkline plc
15.13.1.
Company Details
15.13.2.
Company Overview
15.13.3.
Product Offerings
15.13.4.
Key Developments
15.13.5.
Financial Analysis
15.13.6.
SWOT Analysis
15.13.7.
Business Strategies
15.14. Lupin Pharmaceuticals, Inc.
15.14.1.
Company Details
15.14.2.
Company Overview
15.14.3.
Product Offerings
15.14.4.
Key Developments
15.14.5.
Financial Analysis
15.14.6.
SWOT Analysis
15.14.7.
Business Strategies
15.15. Merck & Co., Inc.
15.15.1.
Company Details
15.15.2.
Company Overview
15.15.3.
Product Offerings
15.15.4.
Key Developments
15.15.5.
Financial Analysis
15.15.6.
SWOT Analysis
15.15.7.
Business Strategies
15.16. Novartis AG
15.16.1.
Company Details
15.16.2.
Company Overview
15.16.3.
Product Offerings
15.16.4.
Key Developments
15.16.5.
Financial Analysis
15.16.6.
SWOT Analysis
15.16.7.
Business Strategies
15.17. Pfizer, Inc.
15.17.1.
Company Details
15.17.2.
Company Overview
15.17.3.
Product Offerings
15.17.4.
Key Developments
15.17.5.
Financial Analysis
15.17.6.
SWOT Analysis
15.17.7.
Business Strategies
15.18. Sanofi
15.18.1.
Company Details
15.18.2.
Company Overview
15.18.3.
Product Offerings
15.18.4.
Key Developments
15.18.5.
Financial Analysis
15.18.6.
SWOT Analysis
15.18.7. Business Strategies
15.19. Teva Pharmaceutical Industries Ltd.
15.19.1.
Company Details
15.19.2.
Company Overview
15.19.3.
Product Offerings
15.19.4.
Key Developments
15.19.5.
Financial Analysis
15.19.6.
SWOT Analysis
15.19.7.
Business Strategies
Note:
This ToC is tentative and can be changed according to the research study
conducted during the course of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.